Information Provided By: 
Fly News Breaks for July 22, 2019
ACAD
Jul 22, 2019 | 20:21 EDT
Piper Jaffray analyst Danielle Brill tells investors in a research note that while her expectations for Acadia's Phase 3 trial of pimavanserin were low, the market did not price this in, and she expects some "modest downside" for the stock in the wake of the primary endpoint failure disclosed by the company. The analyst also sees this as a "clearing event" for Acadia, keeping her Overweight rating and $35 price target on the stock and shifting her focus to the interim DRP trial results expected in the second half of 2019.
News For ACAD From the Last 2 Days
